Author

H. M. Schueler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:scRNA-seq· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. Maurer· 2 shared M. Zenke· 2 shared N. Chatain· 2 shared S. Koschmieder· 2 shared T. H. Bruemmendorf· 2 shared A. Reiter· 1 shared A. S. Sechi· 1 shared A. Simonowski· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Maurer

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CALR frameshift mutations in MPN patient-derived iPS cells accelerate maturation of megakaryocytes

K. Olschok, L. Han, M. A. S. de Toledo, J. Boehnke, M. Grasshoff, I. G. Costa, A. Theocharides, A. Maurer, H. M. Schueler, E. M. Buhl, K. Pannen, J. Baumeister, M. Kalmer, S. Gupta, P. Boor, , S. Koschmieder

This study shows CALR mutations in iPS cells from MPN patients accelerate megakaryocyte maturation and identify hypoxia signaling as a therapeutic target.

Stem Cell Reports · Nov 1, 2021Peer-reviewedCancer Biology

Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic Mastocytosis

M. A. Szymanski de Toledo, M. Gatz, S. Sontag, K. V. Gleixer, G. Eisenwort, K. Feldberg, F. Kluge, R. Guareschi, G. Rossetti, A. S. Sechi, O. Dufva, S. M. Mustjoki, A. Maurer, H. M. Schueler, R. Goetzke, , M. Zenke

This study identifies nintedanib as a novel KIT D816V inhibitor effective against patient-derived neoplastic mast cells in systemic mastocytosis.

bioRxiv · May 6, 2020Cancer Biology